Adjuvant EGFR-TKI in resected EGFR-mutated NSCLC in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter observational study combining retrospective data collection with prospective follow-up to describe how adjuvant EGFR-TKI is used and what outcomes patients experience in routine care. The study will include adults with resected stage IB–III EGFR-mutated NSCLC who started adjuvant EGFR-TKI between July 1, 2023 and June 30, 2026, followed for up to the end of the study period. Data are gathered from 15 sites across China, with follow-up every 12 weeks for the first year and every 24 weeks thereafter. Outcomes will be captured through medical records and telephone interviews, regardless of planned visit schedules. No specific intervention is being tested; the study observes real-world treatment patterns and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed stage IB-III NSCLC on or prior to the index date;
* Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026

Where it's running

• Research Site
  Guangzhou, China Recruiting
• Research Site
  Beijing, China Not yet recruiting
• Research Site
  Chengdu, China Not yet recruiting
• Research Site
  Fuzhou, China Not yet recruiting
• Research Site
  Guangzhou, China Not yet recruiting
• Research Site
  Nanchang, China Not yet recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Urine VOC Test to Detect Lung Cancer in Never Smokers

  A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07871656

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Olive oil before lung cancer surgery to see if it lowers chylothorax

  This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.

  Recruiting Fudan University · Shanghai, Xuhui · NCT07807696

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.